Clinical Trial Update: Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing subcutaneous blinatumomab in combination with ponatinib for Philadelphia chromosome-positive BCR-ABL–positive acute lymphoblast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Drugs mentioned

• BLINCYTO (BLINATUMOMAB)
• Iclusig (ponatinib)

Snippet

Sponsor: University of Alberta | Conditions: Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), BCR-ABL Positive Acute Lymphoblastic Leukemia | Phase 2 | Status: NOT_YET_RECRUITING